Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 17

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 17
---
 |     |   |     |   |     |   |
| Teclistamab  |     | DuoBody    |     | J&J               |     | Multiple myeloma                          |     |                                 |     |   |     |   |     |   |
| Talquetamab  |     | DuoBody    |     | J&J               |     | Multiple myeloma                          |     |                                 |     |   |     |   |     |   |
| Amlenetug    
 (Lu AF82422) |     | UltiMAb    |     | Lundbeck          |     | Multiple system atrophy                   |     |                                 |     |   |     |   |     |   |
| Inclacumab   |     | UltiMAb    |     | Pfizer            |     | Sickle cell disease                       |     |                                 |     |   |     |   |     |   |
| Mim8         |     | DuoBody    |     | Novo Nordisk      |     | Hemophilia A                              |     |                                 |     |   |     |   |     |   |

* UltiMAb transgenic mouse technology licensed from Medarex, a wholly owned subsidiary of Bristol-Myers Squibb.

DARZALEX (daratumumab) – Redefining the treatment of multiple myeloma

• First-in-class human CD38 monoclonal antibody

• Developed and commercialized by J&J under an exclusive worldwide license from Genmab

• Intravenous (IV) formulation approved in combination with other therapies and as monotherapy for certain multiple myeloma indications

• First and only SC CD38-directed antibody approved for the treatment of certain multiple myeloma indications, known as DARZALEX FASPRO in the U.S., and DARZALEX SC in Europe

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 12/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
• SC daratumumab is the first and only approved therapy for AL amyloidosis in the U.S., Europe, and Japan

• Net sales of DARZALEX by J